Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 8, 2003, Pages 2397-2403

  Pérez Victoria, F Javier ^a   Castanys, Santiago ^a   Gamarro, Francisco ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MILTEFOSINE; N ETHYLMALEIMIDE; PHOSPHOLIPID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG UPTAKE; ENDOCYTOSIS; IN VITRO STUDY; INTERNALIZATION; LEISHMANIA DONOVANI; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; TEMPERATURE DEPENDENCE;

ANIMALS; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; ENDOCYTOSIS; ENERGY METABOLISM; FLUORESCENT DYES; LEISHMANIA DONOVANI; PHOSPHOLIPIDS; PHOSPHORYLCHOLINE; PROTEINS; TEMPERATURE; TRANSLOCATION, GENETIC;

EID: 0041767590     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.8.2397-2403.2003     Document Type: Article

References (35)

1. Achterberg, V., and G. Gercken. 1987. Metabolism of ether lysophospholipids in Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 26:277-287.
2. Arthur, G., and R. Bittman. 1998. The inhibition of cell signaling pathways by antitumor ether lipids. Biochim. Biophys. Acta 1390:85-102.
3. Bazill, G. W., and T. M. Dexter. 1990. Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells. Cancer Res. 50:7505-7512.
4. Berdel, W. E. 1991. Membrane-interactive lipids as experimental anticancer drugs. Br. J. Cancer 64:208-211.
5. Diomede, L., F. Colotta, B. Piovani, F. Re, E. J. Modest, and M. Salmona. 1993. Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine. A possible basis for its selective action. Int. J. Cancer 53:124-130.
6. Fleer, E. A., D. Berkovic, H. Eibl, and C. Unger. 1993. Investigations on the cellular uptake of hexadecylphosphocholine. Lipids 28:731-736.
7. Fleer, E. A., D. Berkovic, U. Grunwald, and W. Hiddemann. 1996. Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB. Eur. J. Cancer 32:506-511.
8. Ganguly, N. K. 2002. Oral miltefosine may revolutionize treatment of visceral leishmaniasis. TDR News W. H. O. 68:2.
9. Grant, A. M., P. K. Hanson, L. Malone, and J. W. Nichols. 2001. NBD-labeled phosphatidylcholine and phosphatidylethanolamine are internalized by transbilayer transport across the yeast plasma membrane. Traffic 2:37-50.
10. Herwaldt, B. L. 1999. Leishmaniasis. Lancet 354:1191-1199.
11. Jha, T. K., S. Sundar, C. P. Thakur, P. Bachmann, J. Karbwang, C. Fischer, A. Voss, and J. Berman. 1999. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. 341:1795-1800.
12. Kato, U., K. Emoto, C. Fredriksson, H. Nakamura, A. Ohta, T. Kobayashi, K. Murakami-Murofushi, T. Kobayashi, and M. Umeda. 2002. A novel membrane protein, Ros3p, is required for phospholipid translocation across the plasma membrane in Saccharomyces cerevisiae. J. Biol. Chem. 277:37855-37862.
13. Kean, L. S., R. S. Fuller, and J. W. Nichols. 1993. Retrograde lipid traffic in yeast: identification of two distinct pathways for internalization of fluorescent-labeled phosphatidylcholine from the plasma membrane. J. Cell Biol. 123:1403-1419.
14. Lira, R., L. M. Contreras, R. M. Rita, and J. A. Urbina. 2001. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J. Antimicrob. Chemother. 47:537-546.
15. Lux, H., N. Heise, T. Klenner, D. Hart, and F. R. Opperdoes. 2000. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol. 111:1-14.
16. Martin, O. C., and R. E. Pagano. 1987. Transbilayer movement of fluorescent analogs of phosphatidylserine and phosphatidylethanolamine at the plasma membrane of cultured cells. Evidence for a protein-mediated and ATP-dependent process(es). J. Biol. Chem. 262:5890-5898.
17. Mohandas, N., J. Wyatt, S. F. Mel, M. E. Rossi, and S. B. Shohet. 1982. Lipid translocation across the human erythrocyte membrane. J. Biol. Chem. 257: 6537-6543.
18. Mullin, K. A., B. J. Foth, S. C. Ilgoutz, J. M. Callaghan, J. L. Zawadzki, G. I. McFadden, and M. J. McConville. 2001. Regulated degradation of an endoplasmic reticulum membrane protein in a tubular lysosome in Leishmania mexicana. Mol. Biol. Cell 12:2364-2377.
19. Pagano, R. E., and R. G. Sleight. 1985. Defining lipid transport pathways in animal cells. Science 229:1051-1057.
20. Perez-Victoria, J. M., F. J. Perez-Victoria, A. Parodi-Talice, I. A. Jimenez, A. G. Ravelo, S. Castanys, and F. Gamarro. 2001. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob. Agents Chemother. 45:2468-2474.
21. Pomorski, T., A. Herrmann, P. Muller, G. van Meer, and K. Burger. 1999. Protein-mediated inward translocation of phospholipids occurs in both the apical and basolateral plasma membrane domains of epithelial cells. Biochemistry 38:142-150.
22. Raggers, R. J., T. Pomorski, J. C. Holthuis, N. Kalin, and G. van Meer. 2000. Lipid traffic: the ABC of transbilayer movement. Traffic 1:226-234.
23. Rybczynska, M., M. Spitaler, N. G. Knebel, G. Boeck, H. Grunicke, and J. Hofmann. 2001. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem. Pharmacol. 62:765-772.
24. Rybczynska, M., R. Liu, P. Lu, F. J. Sharom, E. Steinfels, A. D. Pietro, M. Spitaler, H. Grunicke, and J. Hofmann. 2001. MDR1 causes resistance to the antitumour drug miltefosine. Br. J. Cancer 84:1405-1411.
25. Santa-Rita, R. M., H. Santos Barbosa, M. N. Meirelles, and S. L. de Castro. 2000. Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop. 75:219-228.
26. Seifert, K., S. Matu, F. J. Pérez-Victoria, S. Castanys, F. Gamarro, and S. L. Croft. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents, in press.
27. Sleight, R. G., and M. N. Abanto. 1989. Differences in intracellular transport of a fluorescent phosphatidyl choline analog in established cell lines. J. Cell Sci. 939:363-374.
28. Small, G. W., J. C. Strum, and L. W. Daniel. 1997. Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Lipids 32:715-723.
29. Soto, J., J. Toledo, P. Gutierrez, R. S. Nicholls, J. Padilla, J. Engel, C. Fischer, A. Voss, and J. Berman. 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 33:57-61.
30. Sundar, S., A. Makharia, D. K. More, G. Agrawal, A. Voss, C. Fischer, P. Bachmann, and H. W. Murray. 2000. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin. Infect. Dis. 31:1110-1113.
31. Tang, X., M. S. Halleck, R. A. Schlegel, and P. Williamson. 1996. A subfamily of P-type ATPases with aminophospholipid transporting activity. Science 272:1495-1497.
32. Tsutsumi, T., A. Tokumura, and S. Kitazawa. 1998. Undifferentiated HL-60 cells internalize an antitumor alkyl ether phospholipid more rapidly than resistant K562 cells. Biochim. Biophys. Acta 1390:73-84.
33. Wieder, T., W. Reutter, C. E. Orfanos, and C. C. Geilen. 1999. Mechanisms of action of phospholipid analogs as anticancer compounds. Prog. Lipid Res. 38:249-259.
34. Zhang, Z., and J. W. Nichols. 1994. Protein-mediated transfer of fluorescent-labeled phospholipids across brush border of rabbit intestine. Am. J. Physiol. 267:80-86.
35. Zoeller, R. A., M. D. Layne, and E. J. Modest. 1995. Animal cell mutants unable to take up biologically active glycerophospholipids. J. Lipid Res. 36:1866-1875.